US OptionsDetailed Quotes

NVRO241018C2500

Watchlist

3.20
0.000.00%

15min DelayClose Oct 18 15:59 ET

0.00High0.00Low

Nevro Stock Discussion

Jaguar8

Sep 24 07:02

NEWS

$Nevro (NVRO.US)$
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
Nevro Corp. (NYSE: NVRO) has announced the FDA approval and market release of HFX iQ™ with HFX AdaptivAI™, an AI-driven spinal cord stimulation (SCS) system for chronic pain management. This technology leverages insights from over 100,000 patients and more than 100 million data points to provide personalized, responsive pain relief in real time.
Key features of HFX Adaptiv...

Newbee4

Aug 8 06:22

Do you have any thoughts on this?

$Nevro (NVRO.US)$ @Trytosaveabit

Moomoo AI

Feb 25 07:35

Nevro's low P/S ratio may be due to its poor revenue outlook. Shareholders accept this as they anticipate no future revenue surprises. These conditions could continue to limit the share price.

Benign Growth For Nevro Corp. (NYSE:NVRO) Underpins Its Share Price

Moomoo AI

Jan 8 11:41

Nevro's growth strategy, prioritizing expansion over steady profits, is viewed as risky, leading to a rapidly declining share price. Despite insider purchases, the company's overall performance has been disappointing, resulting in an annual loss of 8% for shareholders over five years.

Shareholders in Nevro (NYSE:NVRO) Have Lost 89%, as Stock Drops 10% This Past Week

Moomoo AI

Nov 16, 2023 06:30

Insiders buying shares over the past year, including one at a price higher than current, signals positive views of the company's future. While no insider transactions happened in recent three months, activities over the year suggest firm belief in potential.

Nevro Insider Ups Holding By 59% During Year

Moomoo AI

Oct 10, 2023 07:38

The disappointing performance of Nevro's stock may be due to low growth and profit rates. Despite insider purchases, market sentiment towards Nevro remains negative, possibly an overreaction.

Further Weakness as Nevro (NYSE:NVRO) Drops 9.3% This Week, Taking Three-year Losses to 88%

Moomoo AI

Oct 10, 2023 07:30

Despite Nevro's stock price plummeting, insiders buying shares in the past year, the company's ascent looks doubtful without significant profits and revenue growth.

Further Weakness as Nevro (NYSE:NVRO) Drops 9.3% This Week, Taking Three-year Losses to 88%

Movers and Shakers

Oct 10, 2022 07:55

Columns Today's Pre-Market Stock Movers: RIVN, EDU, TLRY, F and More

Gapping up
News:
• $PyroGenesis Canada (PYR.US)$ +5.9% (announces that the negotiation for the land-based system to destroy PFAS contract has been suspended and discontinued)
• $Immatics (IMTX.US)$ +3.1% (announces a clinical data update for the IMA203)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +1.6% (rising with softness in futures)
• $Nevro (NVRO.US)$ +1.4% (comments on $UnitedHealth (UNH.US)$ medical coverage policy u...

Movers and Shakers

Oct 5, 2022 07:42

Columns Today's Pre-Market Stock Movers: TSLA, F, KORE, AMLX and More

Gapping up
In reaction to earnings/guidance:
$RPM International (RPM.US)$ +2.4%
Other news:
$Radiant Logistics (RLGT.US)$ +6.8% (to restate FY21 earnings)
$Stellus Capital Investment (SCM.US)$ +3.3% (declares Q4 dividends of $0.34 per share)
$Golden Ocean (GOGL.US)$ +2.5% (authorizes new $100 mln share repurchase program)
$iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +1.5% (rising with pull back in stock futures)
$Pebblebrook Hotel Trust (PEB.US)$ +1.3% (se...

Analysts Notebook

May 5, 2022 06:49

Columns Top upgrades and downgrades on 5/5

Upgrades
• $AGNC Investment Corp (AGNC.US)$ : Piper Sandler Upgrades to Overweight from Neutral - PT $13 (from $13.50)
• $Esperion Therapeutics (ESPR.US)$ : JP Morgan Upgrades to Neutral From Underweight
• $Fortinet (FTNT.US)$ : Mizuho Securities Upgrades to Buy from Neutral - PT $350 (from $340)
• $Horizon Technology Finance (HRZN.US)$ : Compass Point Upgrades to Neutral From Sell
• $Momentive Global (MNTV.US)$ : Craig-Hallum Upgrades to Buy from Hold - PT $...

No comment yet